The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.
Open accessAbstract
Necropsy brain tissue from normal (control) patients and patients with depression and dementia was examined for activities of various cholinergic components, and these related to the degree of senile plaque formation and extent of intellectual impairment. Choline acetyltransferase and acetylcholinesterase activities decreased significantly as the mean plaque count rose, and in depressed and demented subjects the reduction in choline acetyltransferase activity correlated with the extent of intellectual impairment as measured by a memory information test; muscarinic cholinergic receptor binding activity remained unchanged with increasing senile plaque formation but butyrylcholinesterase activity increased. The results suggest a close relation between changes in the cholinergic system and Alzheimer's dementia, but the precise role of the system in this disease remains to be elucidated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Self-citation
Cited by
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
CENTRAL CHOLINERGIC SYSTEMS AND COGNITION
Everitt, B. J., & Robbins, T. W. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.649 · Cited by 1,348
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., & Peck, A. (1988) · Annals of Neurology · doi:10.1002/ana.410230206 · Cited by 1,225
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Ernfors, P., Wetmore, C., Olson, L., & Persson, H. (1990) · Neuron · doi:10.1016/0896-6273(90)90090-3 · Cited by 819
Katzman, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604103141506 · Cited by 801
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686
Wilcock, G. K., & Esiri, M. M. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90155-1 · Cited by 608
Acetylcholinesterase inhibitors from plants and fungi
Houghton, P. J., Ren, Y., & Howes, M.-J. (2006) · Natural Product Reports · doi:10.1039/b508966m · Cited by 584
Wilcock, G. K., Esiri, M. M., Bowen, D. M., & Smith, C. C. T. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90045-4 · Cited by 553
Synaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517
The importance of neuritic plaques and tangles to the development and evolution of AD
Tiraboschi, P., Hansen, L. A., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129697.01779.0a · Cited by 477
Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1
WANG, R., YAN, H., & TANG, X.-C. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00255.x · Cited by 470
Kuhl, D. E., Minoshima, S., Fessler, J. A., Ficaro, E. P., Wieland, D. M., Koeppe, R. A., Frey, K. A., & Foster, N. L. (1996) · Annals of Neurology · doi:10.1002/ana.410400309 · Cited by 426
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Cognitive functions of the basal forebrain
Baxter, M. G., & Chiba, A. A. (1999) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(99)80024-5 · Cited by 351
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
Mushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023141545 · Cited by 331
Basal forebrain control of wakefulness and cortical rhythms
Anaclet, C., Pedersen, N. P., Ferrari, L. L., Venner, A., Bass, C. E., Arrigoni, E., & Fuller, P. M. (2015) · Nature Communications · doi:10.1038/ncomms9744 · Cited by 273
Tabet, N. (2006) · Age and Ageing · doi:10.1093/ageing/afl027 · Cited by 285
Muscarinic cholinergic influences in memory consolidation
Power, A. (2003) · Neurobiology of Learning and Memory · doi:10.1016/s1074-7427(03)00086-8 · Cited by 261
Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Suzuki, K., & Irie, T. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09124-6 · Cited by 259
Chan‐Palay, V. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902600205 · Cited by 254
Reduced Numbers of Somatostatin Receptors in the Cerebral Cortex in Alzheimer's Disease
Beal, M. F., Mazurek, M. F., Tran, V. T., Chattha, G., Bird, E. D., & Martin, J. B. (1985) · Science · doi:10.1126/science.2861661 · Cited by 251
The neurobiologie consequences of down syndrome
Coyle, J. T., Oster-Granite, M. L., & Gearhart, J. D. (1986) · Brain Research Bulletin · doi:10.1016/0361-9230(86)90074-2 · Cited by 248
Sahakian, B. J., Owen, A. M., Morant, N. J., Eagger, S. A., Boddington, S., Crayton, L., Crockford, H. A., Crooks, M., Hill, K., & Levy, R. (1993) · Psychopharmacology · doi:10.1007/bf02244644 · Cited by 226
Cognitive Test Performance in Detecting, Staging, and Tracking Alzheimer's Disease
Locascio, J. J., Growdon, J. H., & Corkin, S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540350081020 · Cited by 228
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease
Rafii, M. S., Baumann, T. L., Bakay, R. A. E., Ostrove, J. M., Siffert, J., Fleisher, A. S., Herzog, C. D., Barba, D., Pay, M., Salmon, D. P., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.004 · Cited by 223
Modelling dementia: Effects of scopolamine on memory and attention
Broks, P., Preston, G. C., Traub, M., Poppleton, P., Ward, C., & Stahl, S. M. (1988) · Neuropsychologia · doi:10.1016/0028-3932(88)90004-8 · Cited by 220
Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia.
Román, G. C., & Kalaria, R. N. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.004 · Cited by 213
Brayne, C., & Calloway, P. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92081-8 · Cited by 209
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081813 · Cited by 208
Frick, K. M. (2009) · Hormones and Behavior · doi:10.1016/j.yhbeh.2008.08.015 · Cited by 205
Hernandez, C. M., Kayed, R., Zheng, H., Sweatt, J. D., & Dineley, K. T. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5038-09.2010 · Cited by 204
“…on human AD postmortem tissue indicates that much of the receptor protein is functionally inactivated as a result of association with A peptide (Perry et al., 1978; Banerjee et al., 2000; Martin-Ruiz et al., 2000; Dineley et al., 2001 2002b; Teaktong et al., 2003; Counts et al., 2007; Ren et…”
BackgroundMuir, J. L., Page, K. J., Sirinathsinghji, D. J. S., Robbins, T. W., & Everitt, B. J. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90128-d · Cited by 199
Wong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196
Lanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900705 · Cited by 191
Dalley, J. W. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh052 · Cited by 191
Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model
Molchan, S. E., Martinez, R. A., Hill, J. L., Weingartner, H. J., Thompson, K., Vitiello, B., & Sunderland, T. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90017-g · Cited by 187
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“Its activity is 40–90% lower in AD brains than in control brains, and this reduction correlates with cognitive decline (Perry et al., 1978; Davies, 1979; Wilcock et al., 1982; Sims et al., 1983; Neary et al., 1986; Bierer et al., 1995; Samuel et al., 1997; Cummings, 2000).”
BackgroundNeuroprotective effects of huperzine A: New therapeutic targets for neurodegenerative disease
Zhang, H. Y., & Tang, X. C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.004 · Cited by 174
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Bartus, R. T., Dean, R. L., Sherman, K. A., Friedman, E., & Beer, B. (1981) · Neurobiology of Aging · doi:10.1016/0197-4580(81)90007-5 · Cited by 140
Villard, V., Espallergues, J., Keller, E., Vamvakides, A., & Maurice, T. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379286 · Cited by 139
Pedersen, W. A., Kloczewiak, M. A., & Blusztajn, J. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.8068 · Cited by 134
Parnetti, L., Amenta, F., & Gallai, V. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00312-8 · Cited by 132
Mann, D. M. A., Yates, P. O., & Marcyniuk, B. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90439-2 · Cited by 127
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Dementia in the Elderly: The Silent Epidemic
BECK, J. C., BENSON, D. F., SCHEIBEL, A. B., SPAR, J. E., & RUBENSTEIN, L. Z. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-2-231 · Cited by 97
Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed
Flicker, C., Serby, M., & Ferris, S. H. (1990) · Psychopharmacology · doi:10.1007/bf02244414 · Cited by 95
Hu, L., Wong, T. P., Côté, S. L., Bell, K. F. S., & Cuello, A. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00394-4 · Cited by 90
Behavior and Treatment in Frontotemporal Dementia
Perry, R. J., & Miller, B. L. (2001) · Neurology · doi:10.1212/wnl.56.suppl_4.s46 · Cited by 90
Self-citationEvidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex
Quirion, R., Richard, J., & Dam, T. V. (1985) · Brain Research · doi:10.1016/0006-8993(85)91590-2 · Cited by 88
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84
Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice
Perez, S. E., He, B., Muhammad, N., Oh, K.-J., Fahnestock, M., Ikonomovic, M. D., & Mufson, E. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.002 · Cited by 80
Allen, T. G. J., Abogadie, F. C., & Brown, D. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3979-05.2006 · Cited by 79
The septo-hippocampal system, learning and recovery of function
Niewiadomska, G., Baksalerska-Pazera, M., & Riedel, G. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.03.039 · Cited by 67
Microtubule disruption and cognitive defects: Effect of colchicine on learning behavior in rats
Bensimon, G., & Chermat, R. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90602-x · Cited by 69
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
Abduljawad, A. A., Elawad, M. A., Elkhalifa, M. E. M., Ahmed, A., Hamdoon, A. A. E., Salim, L. H. M., Ashraf, M., Ayaz, M., Hassan, S. S. U., & Bungau, S. (2022) · Molecules · doi:10.3390/molecules27206804 · Cited by 63
“Another cause of AD pathogenesis is the cholinergic neuronal loss, which leads to a gradual decline in the number of cholinergic neurons [33].”
BackgroundDaulatzai, M. A. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1404-6 · Cited by 63
Reinikainen, K. J., Riekkinen, P. J., Jolkkonen, J., Kosma, V.-M., & Soininen, H. (1987) · Brain Research · doi:10.1016/0006-8993(87)91052-3 · Cited by 54
Makhaeva, G. F., Kovaleva, N. V., Boltneva, N. P., Lushchekina, S. V., Astakhova, T. Y., Rudakova, E. V., Proshin, A. N., Serkov, I. V., Radchenko, E. V., Palyulin, V. A., et al. (2020) · Molecules · doi:10.3390/molecules25173915 · Cited by 53
Cholinergic Control in Developing Prefrontal–Hippocampal Networks
Janiesch, P. C., Krüger, H.-S., Pöschel, B., & Hanganu-Opatz, I. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2644-11.2011 · Cited by 49
O’Brien, J., Thomas, A., Ballard, C., Brown, A., Ferrier, N., Jaros, E., & Perry, R. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00944-6 · Cited by 46
Self-citationBalducci, C., Nurra, M., Pietropoli, A., Samanin, R., & Carli, M. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1385-7 · Cited by 42
Extensive Lesions of Cholinergic Basal Forebrain Neurons Do Not Impair Spatial Working Memory
Vuckovich, J. A., Semel, M. E., & Baxter, M. G. (2004) · Learning & Memory · doi:10.1101/lm.63504 · Cited by 39
Beta-amyloid short- and long-term synaptic entanglement
Lanni, C., Fagiani, F., Racchi, M., Preda, S., Pascale, A., Grilli, M., Allegri, N., & Govoni, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.018 · Cited by 29
Effects of Chinese herbal medicine fuzhisan on aged rats
Li, X. L., Wang, D. S., Zhao, B. Q., Li, Q., Qu, H. Y., Zhang, T., Zhou, J. P., & Sun, M. J. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2008.05.018 · Cited by 29
Lai, M. K. P., Tsang, S. W. Y., Garcia-Alloza, M., Minger, S. L., Nicoll, J. A. R., Esiri, M. M., Wong, P. T.-H., Chen, C. P. L.-H., Ramírez, M. J., & Francis, P. T. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.016 · Cited by 29
Foidl, B. M., Do-Dinh, P., Hutter-Schmid, B., Bliem, H. R., & Humpel, C. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.09.014 · Cited by 24
Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?
Ravona-Springer, R., Davidson, M., & Noy, S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/rravonaspringer · Cited by 18
Droogsma, E., van Asselt, D., Diekhuis, M., Veeger, N., van der Hooft, C., & De Deyn, P. P. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000289 · Cited by 15
Phytochemicals in Alzheimer disease, the development of clinical trials
Quinn, J., Kaye, J., Montine, T., & Stackman, R. (2004) · Pharmaceutical Biology · doi:10.3109/138802090893531 · Cited by 8
Metadata
- Authors
- Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1978-11-25
- Volume
- 2
- Issue
- 6150
- Pages
- 1457-1459
- ISSN
- 0007-1447 (ISSN-L)
- 1468-5833
- OpenAlex
- W2004713321
- Cited by
- 2,042
- References
- 1
- FWCI
- 35.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
